FDA Ponders Drug Pricing In Opioid Abuse Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency, of course, cannot consider drug pricing in approval decisions, but is making itself aware as it mulls broader policy changes.
You may also be interested in...
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
FDA’s Naloxone Product Approval Standards May See Changes
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
Naloxone Costs Could Temper Non-Rx Access Even As Distribution Spreads
CVS in 31 states offers naloxone from pharmacists without a prescription and Walgreens offers it in 14, with plans to more than double the program this year. Whether from pharmacists or OTC, "an affordable price is essential if this is to reach the people who need it," says harm reduction advocate Scott Burris.